Paper Details

  1. Home
  2. Paper Details

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.

Author: BissonnetteRobert, ChenRongdean, DayRobert M, GoncalvesJoana, PariserDavid M, SebastianMichael, WaselNorman R

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Apremilast may be a useful oral treatment option for patients with moderate to severe palmoplantar plaque psoriasis. Significantly more patients taking apremilast with moderate to severe palmoplantar psoriasis achieved PPPGA score 0 (clear) or 1 (almost clear) compared with placebo at week 16.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life. OBJECTIVE: We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis. METHODS: A post hoc analysis of data pooled from phase IIb (PSOR-005) and phase III (Efficacy ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaad.2016.02.1164

データ提供：米国国立医学図書館（NLM）

Apremilast for Palmoplantar Psoriasis: A Promising Oasis in the Desert of Psoriasis Treatment

Psoriasis, a chronic skin condition characterized by itchy, scaly patches, can significantly impact quality of life. Palmoplantar psoriasis, a specific type affecting the palms of the hands and soles of the feet, can be particularly challenging to treat. This study investigates the efficacy of apremilast, an oral phosphodiesterase-4 inhibitor, in managing palmoplantar psoriasis. The authors, like skilled desert navigators, carefully analyzed the data from clinical trials to assess the effectiveness of apremilast. Their research, like an oasis in the desert of psoriasis treatment, suggests that apremilast may be a valuable therapeutic option for patients with palmoplantar psoriasis.

Apremilast: A Potential Solution for Difficult-to-Treat Psoriasis

The study demonstrates that apremilast was significantly more effective than placebo in achieving symptom improvement in patients with palmoplantar psoriasis. This finding, like a hidden spring in the desert of psoriasis, offers hope for patients seeking relief from this debilitating condition. The authors encourage further research to explore the long-term benefits of apremilast and its potential to improve the quality of life for patients with palmoplantar psoriasis.

Living with Psoriasis: A Journey Through the Desert of Skin Disease

Psoriasis can be a chronic and challenging condition. Understanding the disease, seeking appropriate treatment, and managing symptoms effectively are crucial for improving quality of life. This research provides a promising glimpse into the potential of apremilast for managing palmoplantar psoriasis, offering hope for a more comfortable and fulfilling journey.

Dr.Camel's Conclusion

This study provides encouraging evidence for the efficacy of apremilast in treating palmoplantar psoriasis. Like a skilled desert guide, researchers continue to explore new treatment options for psoriasis, offering hope and relief for patients living with this challenging skin condition.

Date :
  1. Date Completed 2017-04-12
  2. Date Revised 2017-08-17
Further Info :

Pubmed ID

27021239

DOI: Digital Object Identifier

10.1016/j.jaad.2016.02.1164

Related Literature

Article Analysis
・Effects of apremilast
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.